

# Press Release

## ProStrakan Group plc

### Board Changes

**Galashiels, Scotland – 29 December 2005** – ProStrakan Group plc (“ProStrakan” or “the Company”), the European specialty pharmaceutical company, announces today that Professor Roland Baron, CSO of ProStrakan Group Plc, has informed the company that, under the terms of an agreement entered into between ProSkelia S.A.S. and Professor Baron dated 26<sup>th</sup> April 2005, he does not accept certain changes to his role in the enlarged ProStrakan Group. This triggers a severance payment, under the terms of which Professor Baron will leave the company early in 2006. He steps down from the Board with immediate effect.

#### ***Enquiries:***

#### **ProStrakan**

Wilson Totten, Chief Executive Officer  
Adrian Gardner, Chief Financial Officer  
David Watt, Corp Comms

**Tel: 01896 664000**  
**Tel: 01896 664000**  
**Tel: 01896 664103**

#### **Financial Dynamics**

David Yates / Sarah Macleod

**Tel: 020 7831 3113**

#### **Notes to Editors**

#### **ProStrakan**

ProStrakan Group plc is a rapidly growing international specialty pharmaceutical company engaged in the research, development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets. The Company’s therapeutic focus is on oncology supportive care, bone diseases, women’s health and issues relating to the ageing male. Headquartered in Scotland, the Company’s R&D facilities are situated in Romainville, near Paris, and in Galashiels in Scotland. EU-wide sales and marketing of ProStrakan’s portfolio of products are principally handled by commercial subsidiaries based in the UK, France, Germany and Spain.

ProStrakan floated on the London Stock Exchange in June 2005. In September 2005, the Group announced interim results showing revenues up 78% to £16.5 million.

[www.prostrakan.com](http://www.prostrakan.com)